Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

The evolving role of biologics in the treatment of pediatric psoriasis.

Luu M, Cordoro KM.

Skin Therapy Lett. 2013 Feb;18(2):1-4.

2.

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.

Leman J, Burden AD.

Br J Dermatol. 2012 Nov;167 Suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x. Review.

PMID:
23082811
3.

Use of biologic agents in pediatric psoriasis.

Marji JS, Marcus R, Moennich J, Mackay-Wiggan J.

J Drugs Dermatol. 2010 Aug;9(8):975-86. Review.

PMID:
20684148
4.

Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.

Tan X, Balkrishnan R, Feldman SR.

J Drugs Dermatol. 2013 Mar;12(3):e41-5. Review.

PMID:
23545925
5.

Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.

Carlesimo M, La Pietra M, Arcese A, Di Russo PP, Mari E, Gamba A, Orsini D, Camplone G.

Int J Dermatol. 2012 Oct;51(10):1234-6. doi: 10.1111/j.1365-4632.2011.05166.x. Epub 2012 Mar 14. No abstract available.

PMID:
22416995
6.

Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.

Viguier M, Aubin F, Delaporte E, Pagès C, Paul C, Beylot-Barry M, Goujon C, Rybojad M, Bachelez H; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.

Arch Dermatol. 2012 Dec;148(12):1423-5. doi: 10.1001/2013.jamadermatol.80. No abstract available.

PMID:
23247492
7.

[Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].

Moreno-Ramírez D.

Actas Dermosifiliogr. 2011 May;102(4):241-3. doi: 10.1016/j.ad.2011.02.003. Epub 2011 Apr 9. Spanish. No abstract available.

PMID:
21481332
8.

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

Langley RG.

J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:21-9. doi: 10.1111/j.1468-3083.2011.04412.x. Review.

PMID:
22356632
9.

Treatment of spondyloarthritides with anti-TNFalpha biologic agents.

Braun J.

Reumatismo. 2006 Jan-Mar;58 Spec No.1:71-2. No abstract available.

10.

Eosinophilia during psoriasis treatment with TNF antagonists.

Malisiewicz B, Murer C, Pachlopnik Schmid J, French LE, Schmid-Grendelmeier P, Navarini AA.

Dermatology. 2011;223(4):311-5. doi: 10.1159/000334805. Epub 2012 Feb 2. No abstract available.

PMID:
22301393
11.

Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.

Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.

Br J Dermatol. 2010 Oct;163(4):838-46. doi: 10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2.

PMID:
20649798
12.

Treatment of generalized vitiligo with anti-TNF-α Agents.

Alghamdi KM, Khurrum H, Taieb A, Ezzedine K.

J Drugs Dermatol. 2012 Apr;11(4):534-9.

PMID:
22453596
13.
14.

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.

Mossner R, Reich K.

Curr Probl Dermatol. 2009;38:107-36. doi: 10.1159/000232307. Epub 2009 Jul 28. Review.

PMID:
19710553
15.

The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.

Gallo E, Cabaleiro T, Román M, Solano-López G, Abad-Santos F, García-Díez A, Daudén E.

Br J Dermatol. 2013 Oct;169(4):819-29. doi: 10.1111/bjd.12425.

PMID:
23662788
16.

Anti-TNF agents for the treatment of psoriasis.

Kircik LH, Del Rosso JQ.

J Drugs Dermatol. 2009 Jun;8(6):546-59. Review.

PMID:
19537380
17.

Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.

Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.

Dermatology. 2012;225(4):312-9. doi: 10.1159/000345623. Epub 2012 Dec 28.

PMID:
23295383
18.

Anti-TNF-alpha therapy in childhood pustular psoriasis.

Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS.

Dermatology. 2006;213(4):350-2. No abstract available.

PMID:
17135745
19.

Tumor necrosis factor antagonists in the therapy of psoriasis.

Mössner R, Schön MP, Reich K.

Clin Dermatol. 2008 Sep-Oct;26(5):486-502. doi: 10.1016/j.clindermatol.2007.10.030. Review.

PMID:
18755367
20.

Long-term management of erythrodermic psoriasis with anti-TNF agents.

Romero-Maté A, García-Donoso C, Martinez-Morán C, Hernández-Núñez A, Borbujo J.

Dermatol Online J. 2010 Jun 15;16(6):15.

PMID:
20579470

Supplemental Content

Support Center